The proteasome inhibitor bortezomib inhibits T cell-dependent inflammatory responses

Journal of Leukocyte Biology

Volumn 88, Issue 1, 2010, Pages 117-122

  Yanaba, Koichi ^a   Yoshizaki, Ayumi ^a   Muroi, Eiji ^a   Hara, Toshihide ^a   Ogawa, Fumihide ^a   Shimizu, Kazuhiro ^a   Sato, Shinichi ^b  

^a NAGASAKI UNIVERSITY GRADUATE SCHOOL OF BIOMEDICAL SCIENCES   (Japan)

^b UNIVERSITY OF TOKYO   (Japan)

Author keywords

Animal models; Cytokines; Immunotherapy; Skin

Indexed keywords

BORTEZOMIB; GAMMA INTERFERON; INTERLEUKIN 10; INTERLEUKIN 17; INTERLEUKIN 4; INTERLEUKIN 6; LIPOCORTIN 5; OXAZOLONE; BORONIC ACID DERIVATIVE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; PROTEASOME; PROTEINASE INHIBITOR; PYRAZINE DERIVATIVE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL INFILTRATION; CONTACT ALLERGY; CONTROLLED STUDY; CYTOKINE PRODUCTION; DRUG EFFECT; INFLAMMATION; INFLAMMATORY CELL; LYMPH NODE; MOUSE; NONHUMAN; OTITIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; ANIMAL; BIOSYNTHESIS; C57BL MOUSE; DRUG ANTAGONISM; IMMUNOLOGY; SKIN ALLERGY; T LYMPHOCYTE;

ANIMALIA; MUS;

ANIMALS; APOPTOSIS; BORONIC ACIDS; DERMATITIS, ALLERGIC CONTACT; INTERFERON-GAMMA; MICE; MICE, INBRED C57BL; NF-KAPPA B; PROTEASE INHIBITORS; PROTEASOME ENDOPEPTIDASE COMPLEX; PYRAZINES; T-LYMPHOCYTES;

EID: 77954677747     PISSN: 07415400     EISSN: None     Source Type: Journal    
DOI: 10.1189/jlb.1009666     Document Type: Article

References (27)

1. Kripke, M. L., Munn, C. G., Jeevan, A., Tang, J. M., Bucana, C. (1990) Evidence that cutaneous antigen-presenting cells migrate to regional lymph nodes during contact sensitization. J. Immunol. 145, 2833-2838. (Pubitemid 20382549)
2. + type 1 cytotoxic T cells both play a crucial role in the full development of contact hypersensitivity. J. Immunol. 165, 6783-6790.
3. King, R. W., Deshaies, R. J., Peters, J. M., Kirschner, M. W. (1996) How proteolysis drives the cell cycle. Science 274, 1652-1659. (Pubitemid 26414887)
4. Ciechanover, A., Schwartz, A. L. (1998) The ubiquitin-proteasome pathway: the complexity and myriad functions of proteins death. Proc. Natl. Acad. Sci. USA 95, 2727-2730.
5. Baumeister, W., Walz, J., Zuhl, F., Seemuller, E. (1998) The proteasome: paradigm of a self-compartmentalizing protease. Cell 92, 367-380.
6. Adams, J. (2004) The proteasome: a suitable antineoplastic target. Nat. Rev. Cancer 4, 349-360.
7. Richardson, P. G., Hideshima, T., Anderson, K. C. (2003) Bortezomib (PS-341): a novel, first-in-class proteasome inhibitor for the treatment of multiple myeloma and other cancers. Cancer Control 10, 361-369. (Pubitemid 37296062)
8. Neubert, K., Meister, S., Moser, K., Weisel, F., Maseda, D., Amann, K., Wiethe, C., Winkler, T. H., Kalden, J. R., Manz, R. A., Voll, R. E. (2008) The proteasome inhibitor bortezomib depletes plasma cells and protects mice with lupus-like disease from nephritis. Nat. Med. 14, 748-755.
9. Luo, H., Wu, Y., Qi, S., Wan, X., Chen, H., Wu, J. (2001) A proteasome inhibitor effectively prevents mouse heart allograft rejection. Transplantation 72, 196-202. (Pubitemid 32729334)
10. Sun, K., Welniak, L. A., Panoskaltsis-Mortari, A., O'Shaughnessy, M. J., Liu, H., Barao, I., Riordan, W., Sitcheran, R., Wysocki, C., Serody, J. S., Blazar, B. R., Sayers, T. J., Murphy, W. J. (2004) Inhibition of acute graft-versus-host disease with retention of graft-versus-tumor effects by the proteasome inhibitor bortezomib. Proc. Natl. Acad. Sci. USA 101, 8120-8125.
11. Blanco, B., Perez-Simon, J. A., Sanchez-Abarca, L. I., Carvajal-Vergara, X., Mateos, J., Vidriales, B., Lopez-Holgado, N., Maiso, P., Alberca, M., Villaron, E., Schenkein, D., Pandiella, A., San Miguel, J. (2006) Bortezomib induces selective depletion of alloreactive T lymphocytes and decreases the production of Th1 cytokines. Blood 107, 3575-3583.
12. Naujokat, C., Daniel, V., Bauer, T. M., Sadeghi, M., Opelz, G. (2003) Cell cycle- and activation-dependent regulation of cyclosporin A-induced T cell apoptosis. Biochem. Biophys. Res. Commun. 310, 347-354.
13. + phenotype controls T cell-dependent inflammatory responses. Immunity 28, 639-650.
14. Marcelo, C. L., Kim, Y. G., Kaine, J. L., Voorhees, J. J. (1978) Stratification, specialization, and proliferation of primary keratinocyte cultures. Evidence of a functioning in vitro epidermal cell system. J. Cell Biol. 79, 356-370.
15. Bigby, M., Vargas, R., Sy, M. S. (1989) Production of hapten-specific T cell hybridomas and their use to study the effect of ultraviolet B irradiation on the development of contact hypersensitivity. J. Immunol. 143, 3867-3872. (Pubitemid 20012566)
16. Meijerink, J., Mandigers, C., van de Locht, L., Tonnissen, E., Goodsaid, F., Raemaekers, J. (2001) A novel method to compensate for different amplification efficiencies between patient DNA samples in quantitative real-time PCR. J. Mol. Diagn. 3, 55-61.
17. Mayo, M. W., Norris, J. L., Baldwin, A. S. (2001) Ras regulation of NF-κB and apoptosis. Methods Enzymol. 333, 73-87.
18. + T cells. Immunology 124, 234-246.
19. Fissolo, N., Kraus, M., Reich, M., Ayturan, M., Overkleeft, H., Driessen, C., Weissert, R. (2008) Dual inhibition of proteasomal and lysosomal proteolysis ameliorates autoimmune central nervous system inflammation. Eur. J. Immunol. 38, 2401-2411.
20. Mori, T., Kabashima, K., Yoshiki, R., Sugita, K., Shiraishi, N., Onoue, A., Kuroda, E., Kobayashi, M., Yamashita, U., Tokura, Y. (2008) Cutaneous hypersensitivities to hapten are controlled by IFN-γ-upregulated keratinocyte Th1 chemokines and IFN-γ-downregulated Langerhans cell Th2 chemokines. J. Invest. Dermatol. 128, 1719-1727.
21. + T cytotoxic 1 cells inducing keratinocyte apoptosis. J. Immunol. 168, 3079-3087.
22. + T cell-mediated contact hypersensitivity. J. Exp. Med. 189, 779-786.
23. Obeng, E. A., Carlson, L. M., Gutman, D. M., Harrington Jr., W. J., Lee, K. P., Boise, L. H. (2006) Proteasome inhibitors induce a terminal unfolded protein response in multiple myeloma cells. Blood 107, 4907-4916.
24. Naujokat, C., Hoffmann, S. (2002) Role and function of the 26S proteasome in proliferation and apoptosis. Lab. Invest. 82, 965-980.
25. Vanderlugt, C. L., Rahbe, S. M., Elliott, P. J., Dal Canto, M. C., Miller, S. D. (2000) Treatment of established relapsing experimental autoimmune encephalomyelitis with the proteasome inhibitor PS-519. J. Autoimmun. 14, 205-211.
26. Palombella, V. J., Conner, E. M., Fuseler, J. W., Destree, A., Davis, J. M., Laroux, F. S., Wolf, R. E., Huang, J., Brand, S., Elliott, P. J., Lazarus, D., McCormack, T., Parent, L., Stein, R., Adams, J., Grisham, M. B. (1998) Role of the proteasome and NF-κB in streptococcal cell wall-induced polyarthritis. Proc. Natl. Acad. Sci. USA 95, 15671-15676.
27. Elliott, P. J., Pien, C. S., McCormack, T. A., Chapman, I. D., Adams, J. (1999) Proteasome inhibition: a novel mechanism to combat asthma. J. Allergy Clin. Immunol. 104, 294-300.